Edition:
United States

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

4.84USD
15 Dec 2017
Change (% chg)

$0.09 (+1.89%)
Prev Close
$4.75
Open
$4.74
Day's High
$4.97
Day's Low
$4.64
Volume
188,337
Avg. Vol
86,094
52-wk High
$11.79
52-wk Low
$3.30

Latest Key Developments (Source: Significant Developments)

Ocular Therapeutix posts Q3 loss per share $0.54
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.54.Q3 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.Ocular Therapeutix Inc - cash and cash equivalents at Sept 30, 2017 $51.2 million versus $32.9 million at Dec 31,2016‍​.Ocular Therapeutix - expects cash, cash equivalents to be enough to fund operating expenses, debt service obligations, capital expenditures into Q4 of 2018​.  Full Article

Ocular Therapeutix Q2 loss per share $0.64
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Ocular Therapeutix Inc :Ocular therapeutix™ reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.64.Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Ocular Therapeutix to eliminate 26 positions across organization
Tuesday, 1 Aug 2017 05:12pm EDT 

Aug 1 (Reuters) - Ocular Therapeutix Inc ::Ocular Therapeutix says on july 31, board of directors approved a strategic restructuring to eliminate a portion of company's workforce - sec filing.Ocular Therapeutix - company will eliminate 26 positions across organization, representing approximately nineteen percent of company's workforce.Currently expects to substantially complete restructuring and to record restructuring charges in q3 of 2017.Currently anticipates incurring total restructuring costs of approximately $1.5 million.Ocular says co continuing to review potential impact of restructuring; unable to estimate any additional restructuring costs or charges at this time.  Full Article

Ocular Therapeutix receives complete response letter from FDA for Dextenza NDA
Tuesday, 11 Jul 2017 05:00pm EDT 

July 11 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix™ receives complete response letter from fda for dextenza™ nda.Ocular Therapeutix inc says outstanding items pertain to form fda-483 close-out of manufacturing deficiencies and analytical testing.Ocular Therapeutix inc says complete response letter states that fda has determined that it cannot approve nda in its present form.Ocular Therapeutix -crl acknowledges receipt of co's nda amendment dated july 10, 2017 and states amendment was not reviewed prior to fda's action of crl.Ocular Therapeutix Inc says as a result, fda did not have opportunity to review company's close-out response prior to issuing crl.Ocular Therapeutix -FDA indicated applicable sections of amendment submitted by ocular could be incorporated when responding to deficiencies noted in crl.Ocular Therapeutix Inc says satisfactory resolution of manufacturing deficiencies detailed in form fda-483 is required before nda may be approved.Ocular Therapeutix -fda's letter did not identify any efficacy or safety concerns with respect to clinical data for dextenza provided in nda.Ocular Therapeutix -fda's letter did not identify any need for additional clinical trials for nda approval.  Full Article

Ocular Therapeutix announces executive transition plans
Thursday, 22 Jun 2017 04:05pm EDT 

June 22 (Reuters) - Ocular Therapeutix Inc -:Ocular Therapeutix announces executive transition plans.Says Antony Mattessich to assume CEO role in September 2017.Says Amar Sawhney to transition to executive chairman of board.Ocular Therapeutix Inc - to facilitate Mattessich's election to board of directors, James Garvey has resigned from board.  Full Article

Ocular Therapeutix presents additional phase 3 data results for Dextenza
Monday, 8 May 2017 08:00am EDT 

May 8 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix presents additional phase 3 data and patient reported outcomes results for Dextenza at the American Society of Cataract and Refractive Surgery (ASCRS) symposium.Says U.S. FDA has set a target action date under prescription drug user fee act (PDUFA) of July 19, 2017.There were no treatment-related serious adverse events (SAES) and Dextenza was well tolerated in all clinical trials.PDUFA date of July 19, 2017 for decision regarding potential approval of Dextenza for treatment of ocular pain following ophthalmic surgery.Subject to approval of NDA for post-surgical ocular pain by FDA, Ocular Therapeutix intends to submit supplement to NDA for Dextenza.No patients experienced any adverse events resulting in study withdrawal.  Full Article

Ocular Therapeutix reports Q1 loss per share of $0.58
Friday, 5 May 2017 07:30am EDT 

May 5 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix reports first quarter 2017 financial results.Q1 loss per share $0.58.Q1 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.Generated $0.5 million in revenue during three-month period ended March 31, 2017 from product sales of Resure sealant.  Full Article

Ocular Therapeutix appoints George Migausky interim CFO
Thursday, 6 Apr 2017 08:00am EDT 

Ocular Therapeutix Inc - : Ocular Therapeutix appoints George Migausky as interim chief financial officer . Company continues to evaluate candidates for permanent cfo role .Migausky replaces brad smith who recently relinquished his role as cfo at company.  Full Article

Ocular Therapeutix- Bradford Smith notified on march 20 of his resignation from his position as CFO, effective March 31, 2017
Monday, 20 Mar 2017 04:54pm EDT 

Ocular Therapeutix Inc : Ocular Therapeutix- Bradford Smith notified on March 20 of his resignation from his position as CFO of company, effective march 31, 2017 - sec filing .Ocular Therapeutix- Co's coo, will assume roles of principal financial officer, principal accounting officer on interim basis, effective April 1, 2017.  Full Article

Ocular Therapeutix announced positive results of patient experience study of Dextenza
Wednesday, 15 Mar 2017 08:00am EDT 

Ocular Therapeutix Inc : Ocular Therapeutix Inc - announced positive results of patient experience study of dextenza (dexamethasone insert) 0.4 mg for intracanalicular use . Nda for dextenza is currently under review by fda for treatment of ocular pain occurring after ophthalmic surgery . Fda has set a pdufa target action date for july 19, 2017 . Ocular therapeutix - intends to submit an nda supplement for dextenza to broaden its label to include a post-surgical inflammation indication .All patients reported that intracanalicular insert was comfortable.  Full Article

BRIEF-Ocular Therapeutix posts Q3 loss per share $0.54

* Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update